Search results
Results from the WOW.Com Content Network
Azelastine was patented in 1971 and came into medical use in 1986. [10] It is available as a generic medication. [3] [11] In 2022, it was the 124th most commonly prescribed medication in the United States, with more than 5 million prescriptions. [12] [13]
Actuation of a nasal spray bottle, ... the combination azelastine/fluticasone was the 299th most commonly prescribed medication in the United States, with more than ...
Rhinitis medicamentosa (or RM, also known as rebound congestion) is a condition of rebound nasal congestion suspected to be brought on by extended use of topical decongestants (e.g., oxymetazoline, phenylephrine, xylometazoline, and naphazoline nasal sprays) and certain oral medications (e.g., sympathomimetic amines and various 2-imidazolines) that constrict blood vessels in the lining of the ...
Cromolyn Nedocromil. Mast cell stabilizers are medications used to prevent or treat certain allergic disorders. They block mast cell degranulation, stabilizing the cell and thereby preventing the release of histamine and related mediators.
The research which does exist is mostly short-term studies or studies which look at too few people to make general assumptions. [1] Another gap in the research is in information reporting the health effects for individuals with long-term allergies who take antihistamines for a long period of time. [1]
Carbon disulfide can also be used as a catalyst in the last step. [18] When using para-toluenesulfonic acid, the resulting salt can be basified and extracted with hydrochloric acid to produce xylometazoline hydrochloride , which is the main form used in medications.
Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due to rosacea in adults.
For bottle-to-bottle recycling, the bottles have to be decontaminated which was achieved by introducing "super-clean recycling processes," which in the US was done for the first time in 1991. [5] These processes clean "recycled PET flakes to contamination levels similar to virgin PET pellets," so that they can be reused as beverage containers. [5]